{"entity":{"id":"nct06678659","kind":"trial","name":"A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","aka":[],"tldr":"A phase 1/2 trial of REC-1245 in non-Hodgkin lymphoma, run by Recursion Pharmaceuticals Inc., now recruiting.","summary":"A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer is a phase 1/2 interventional study registered as NCT06678659 by Recursion Pharmaceuticals Inc., with 170 participants planned, started 2024-11-21 and due to reach its primary completion in 2028-10-30. Interventions recorded: REC-1245.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06678659","url":"https://clinicaltrials.gov/study/NCT06678659"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["recursion"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06678659","phase":"1/2","setting":"A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","sponsor":"Recursion Pharmaceuticals Inc.","enrolled":170,"outcomes":[]},"route":"/trials/nct06678659/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"company":[{"id":"recursion","kind":"company","name":"Recursion Pharmaceuticals","route":"/companies/recursion/"}]}}